Greenwich LifeSciences Stock
Greenwich LifeSciences, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Snehal S. Patel
- Employees
- 13
- Market cap
- $214 M
- IPO
- 25/09/2020
Greenwich LifeSciences, Inc. functions as a clinical-stage biopharmaceutical company, dedicated to developing innovative cancer immunotherapies. These treatments are primarily focused on breast cancer and other HER2/neu-positive malignancies. Its flagship therapeutic candidate is GP2, an immunotherapy which has…
Greenwich LifeSciences stock: price history
1D
-5.0%
1W
-12.0%
1M
-6.9%
6M
-47.5%
YTD
-30.7%
1Y
+49.7%
2Y
+4.1%
5Y
-61.7%
10Y
–
Next earnings date
Next earnings date
13/11/2026 (in 27 days)
Volatility around earnings
~44% weaker price swings than usual
Ask the agents about Greenwich LifeSciences
Analyst assessment of Greenwich LifeSciences
PRICE TARGET LOW
US$50.00
CONSENSUS
US$50.00
MEDIAN
US$50.00
PRICE TARGET HIGH
US$50.00
0
STRONG BUY
2
BUY
0
HOLD
0
SELL
0
STRONG SELL
2
TOTAL · Buy
As of: 21/07/2026
Greenwich LifeSciences stock metrics
P/E
-9.45
P/B
68.25
EV/EBITDA
-9.44
RETURN ON EQUITY
-126.7%
NET MARGIN
0.0%
DEBT/EQUITY
0
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
52.1%
FLOAT SHARES
7,645,732
AVG. DAILY VOLUME (30D)
127,542
Insider transactions (SEC)
Patel Snehal
Patel Snehal
Patel Snehal
Patel Snehal
Patel Snehal
Institutional holders
Comparable stocks
Frequently asked questions about Greenwich LifeSciences stock
What does Greenwich LifeSciences do?
Greenwich LifeSciences, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Snehal S. Patel, the company employs around 13 people.
The IPO was on 25/09/2020; the stock trades on NASDAQ under the ticker GLSI.
What do analysts say about Greenwich LifeSciences stock?
2 analysts rate the stock, the consensus is Buy (as of 21/07/2026).
The average price target is US$50.00, ranging from US$50.00 to US$50.00, with a median of US$50.00.
This is an external assessment, not a statement by Market Jury.
When does Greenwich LifeSciences report next?
The next earnings date is 13/11/2026.
Around past earnings, price swings were roughly -44% stronger than usual.
Does Greenwich LifeSciences pay a dividend?
No, Greenwich LifeSciences currently does not pay a dividend.
Which stocks are comparable to Greenwich LifeSciences?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Greenwich LifeSciences stock analyzed?
Clicking "Analyze stock" lets five strategies assess Greenwich LifeSciences against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.